Our results revealed fusion partners of TFE3 and TFEB, found correlations between fusion types and prognosis, identified the key genomic alterations in the development and progression of the disease, illustrated the functions of disease-related proteins, highlighted the biologic features of post-translational modifications, discovered molecular subtypes and immune subtypes, and suggested several potential therapeutic targets for the treatment of tRCC. This evidence concerns the gene TFE3 and renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions.